Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1627
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18570555 | E3 Ligase Inhibitors and Methods of Use Thereof | Non-Final OA | The Regents of the University of California |
| 17760298 | THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR FOR USE IN TREATING BRAF MUTANT NSCLC | Final Rejection | Novartis AG |
| 18555218 | CRYSTALLINE FORM OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Non-Final OA | LG CHEM, LTD. |
| 18597021 | Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | Non-Final OA | Nacuity Pharmaceuticals, Inc. |
| 18347896 | Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | Non-Final OA | Nacuity Pharmaceuticals, Inc. |
| 17936654 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17604560 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Non-Final OA | Board of Regents, The University of Texas System |
| 17753487 | TREATMENT OF TRAUMATIC ENCEPHALOPATHY BY FIBROBLASTS AND THERAPEUTIC ADJUVANTS | Non-Final OA | FIGENE, LLC |
| 18477665 | COMPOSITIONS AND METHODS FOR DETERRING OVIPOSITION BY FRUIT FLIES | Non-Final OA | The United States of America, as represented by The Secretary of Agriculture |
| 18574774 | COMPOSITIONS FOR TREATMENT OF HAIR LOSS | Non-Final OA | INNOCAN PHARMA LTD |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | Non-Final OA | APREA THERAPEUTICS, INC. |
| 18044236 | TREATMENT REGIMENS FOR EXON-20 INSERTION MUTANT EGFR CANCERS | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 17920000 | DRUG ANTIBODY CONJUGATES | Non-Final OA | PHARMA MAR, S.A. |
| 18505192 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Non-Final OA | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. |
| 18505538 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Non-Final OA | Opna Bio SA |
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | Non-Final OA | The Scripps Research Institute |
| 18482098 | CDK Inhibitors And Their Use As Pharmaceuticals | Non-Final OA | Prelude Therapeutics Incorporated |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | Non-Final OA | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 17906893 | KCNT1 INHIBITORS AND METHODS OF USE | Non-Final OA | Praxis Precision Medicines, Inc. |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | Final Rejection | Bausch Health Ireland Limited |
| 18252694 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | ORCOSA INC. |
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | Non-Final OA | NUCHIDO LIMITED |
| 18040596 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Non-Final OA | REZUBIO PHARMACEUTICALS CO., LTD |
| 17999779 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Final Rejection | HONGYUN BIOTECH CO., LTD. |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | Non-Final OA | Edgewise Therapeutics, Inc. |
| 17359567 | HERBAL PREPARATION-ENRICHED CANNABINOID COMPOSITION AND METHODS OF TREATMENT | Final Rejection | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. |
| 17792468 | COMBINATION FOR THE TREATMENT OF CANCER AND APPLICATION THEREOF | Non-Final OA | EVERFRONT BIOTECH INC. |
| 17782592 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Non-Final OA | Programmable Medicine Operating Company |
| 17642641 | COMPOSITIONS AND METHODS FOR RESCUING RETINAL AND CHOROIDAL STRUCTURE AND FUNCTION | Non-Final OA | OCUNEXUS THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy